AI is moving quickly into the biopharma field. Commercial organizations are applying the technology to pre-call planning, reporting, routing, and medical teams are using it to speed up how they manage inquiries. The tools themselves can be in place within weeks, and that is when the harder work begins for the people expected to use them.
Reps are asked to change how they work with CRM systems that many already find cumbersome, often across several tools at once. Even when the intelligence behind those tools improves, the user experience changes. For a rep who opens a laptop for ten minutes between calls, that is a significant shift. Reactions vary widely. Their managers may be challenged in how best to support them.
The odds of adoption improve considerably when leaders at every level are prepared to guide their people through change. In our work with biopharma commercial and medical leaders, three questions come up consistently.
Why do AI rollouts stall with biopharma field teams?
Large-scale change has a poor track record. Michael Beer and Nitin Nohria reported in Harvard Business Review that about 70 percent of change initiatives fail. New AI programs likely face the same odds. The reason lies in the gap between change and transition. Change is the event: a new tool, a new workflow, a new report. Transition is how each person responds to that event, and it is different for every individual.
William Bridges, whose work shaped how the field understands transition, showed that people move through it in stages. In the first, they are preoccupied with what the change means for them personally. Only after those concerns are addressed can they turn their attention to performance and customers. Most AI programs are planned with care on the change side, with use cases, training schedules, and communications in place before launch. The transition gets far less attention, and that is where adoption is decided. In most AI rollouts, first-line managers are often only half a step ahead of their reps, which leaves no one positioned to help each person through those stages.
How do biopharma leaders prepare managers to lead an AI rollout?
We have rarely seen a field change hold when managers were left to work out supporting their team’s transition on their own. Preparation starts with the leaders themselves. After a change is announced, people often look to their direct manager’s reaction to decide how to respond. Leaders need to work through their own doubts before they can help anyone else.
The 5C’s of Transition Leadership® provides leaders with a sequence for this work:
- Commit by owning the change and preparing to lead. Leaders manage their own reactions, understand the business case for AI, and work out what it means for their role.
- Construct a plan to address business impact and risks. Leaders keep current goals and customer relationships on track through the rollout and anticipate the risks to individual productivity, engagement, and retention.
- Create a high-performing team to deliver results. Leaders clarify roles, goals, and rules of engagement for working with AI, often through a team jump start.
- Coach direct reports through the transition. Leaders meet one-on-one with each person to work through their individual challenges.
- Calibrate to ensure success. Leaders track adoption and adjust as the team learns.
In an AI rollout, Construct and Coach carry the most weight. Construct keeps the business running while the change lands: which current goals still apply, which accounts need extra attention while reps learn new tools, and where the rollout could disrupt customers. Construct also includes proactively thinking through the risks during the transition and building mitigation strategies. Coach turns to the individual: the veteran rep who has built a career on a personal planning routine, the new hire who will adopt quickly but may lean too hard on the recommendations, the account director concerned that AI-generated insights will shape how performance is judged. Transition coaching helps each person manage their emotions, build confidence, and reinforce their commitment, so they are functioning in the new reality as quickly as possible. Each conversation produces an Individual Transition Plan focused on short-term needs. In our engagements that typically means one-on-one conversations with each direct report identifying challenges and developing plans to close those gaps. Leaders also need to watch for retention risk, because top performers are often the first to leave when a change feels uncertain.
Through this work, leaders also build the conditions adoption depends on: clarity about the business opportunity and each role’s part in it, trust that the tools are secure, fair, and subject to human oversight, the AI literacy and critical judgment to use them well, and steady support through the transition.
How do you know whether field teams are adopting AI?
Log-in counts show that people opened a tool. They say little about whether anyone changed how they work. Calibrate, the fifth C, treats adoption the way a physician treats a new therapy: check how it is working, then adjust the dose. That tracking has to happen at three levels because change only holds when the organization supports it, team leaders reinforce it, and individuals work through it.
- Organization: Is sponsorship visible, is governance clear, and is AI built into the daily workflow? One useful measure is the share of customer interactions in which an AI recommendation shapes call planning.
- Team: Are managers coaching to the new ways of working, recognizing early adopters, and surfacing promising use cases for others to try?
- Individual: Are people building AI literacy and the judgment to question a recommendation? Is their daily work actually changing?
Programs that measure only one level miss where adoption has stalled. Leading indicators at all three show it early enough to recalibrate, and they guard against a common cause of failure: pushing adoption faster than people can absorb it. Large-scale change takes sustained effort over months.
Calibration also builds change agility, the ability to move with balance, speed, and flexibility. That capability matters because AI will keep changing. Each new tool, update, and use case is another change, and leaders who have worked through the 5C’s once are better prepared for the next one.
For leaders planning an AI rollout in the field, a few criteria are worth weighing when selecting a partner.
Who helps biopharma companies lead AI adoption in the field?
Look for a partner that:
- Equips your leaders to coach people through the transition, in addition to planning and communicating the change.
- Understands biopharma commercial and medical roles and the customers they engage.
- Measures adoption by behavior changes at the organization, team, and individual levels.
WLH Consulting & Learning Solutions (“WLH”) brings all three, using the 5C’s of Transition Leadership® to prepare leaders at every level to guide their teams through AI-related change. If your organization is planning an AI rollout, or is already in the middle of one, we would welcome a conversation.
